


AMENDMENTS TO THE CLAIMS

1. (currently amended): A compound having the formula:



and pharmaceutically acceptable salts thereof; wherein:

W is NR^1R^2 or $\text{NR}^1 - (\text{CR}^1_2)_n - \text{NR}^3\text{R}^4$;

Z is OR_2 , NH_2 , NR^1R^2 or $\text{NR}^1 - (\text{CR}^1_2)_n - \text{NR}^3\text{R}^4$;

wherein in NR^1R^2 and NR^3R^4 , R^1 and R^2 together with N and R^3 and R^4 together with N may form an optionally substituted 5-6 membered ring containing N, O, or S;

A is H, halo or NR^1_2 ;

R^1 and R^3 are independently H or a C_{1-6} alkyl;




R^2 is a C_{1-10} alkyl or C_{2-10} alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a C_{3-6} cycloalkyl, aryl, or a 5-14 membered heterocyclic ring containing N, O, or S; or R^2 is an aryl, heteroaryl, or an optionally substituted 5-14 membered heterocyclic ring containing N, O, or S;


R^4 is H or a C_{1-10} alkyl or C_{2-10} alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or a 5-6 membered heterocyclic ring;

m is 1-2;

n is 1-6;

Y is selected from the group consisting of






where R^6 is a substituent at any position on the ring or fused ring; and is H, OR^1 , C_{1-6} alkyl, C_{2-6} alkenyl, each optionally substituted by halo, $[C=O]$ $C=O$ or one or more heteroatoms; ~~or R^6 is an inorganic substituent;~~ or two adjacent R^6 is linked to obtain a 5-6 membered substituted or unsubstituted carbocyclic or heterocyclic ring, optionally fused to an additional substituted or unsubstituted carbocyclic or heterocyclic ring;

Q is CH or N;

and X is O, NH, or S;


~~provided that W is not hydroxy or ethoxy when Y is 2-thiazolyl or Z is 3-amino-1-pyrrolidinyl.~~

2. (original): The compound of claim 1, wherein A is halo.
3. (original): The compound of claim 2, wherein said halo is fluoro.
4. (previously presented): The compound of claim 1, wherein Y has the formula



where X is S and each R_6 is H;

or the formula



where X is S, Q is CH, and each R_6 is H.

5. (original): The compound of claim 1, wherein W and Z are independently NR^1R^2 .

6. (currently amended): The compound of claim 5, wherein R^1 is H and R^2 is a C_{1-10} alkyl substituted with an amine, a C_{3-6} cycloalkyl, aryl or a 5-14 membered heterocyclic ring containing one or more N, O or S.

7. (original): The compound of claim 6, wherein said 5-14 membered heterocyclic ring is selected from the group consisting of tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-*b*]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, and 2,3,4,4a,9,9a-hexahydro-1H- β -carboline.

8. (previously presented): The compound of claim 5, wherein R^1 is H and R^2 is an aryl, tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-*b*]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, or 2,3,4,4a,9,9a-hexahydro-1H- β -carboline, each optionally substituted with an amino or another heterocyclic ring.

9. (canceled)

10. (previously presented): The compound of claim 1, wherein W is NR^1R^2 , and R^1 and R^2 together with N form an optionally substituted 5-14 membered ring containing one or more N, O or S.

11. (original): The compound of claim 10, where NR^1R^2 is morpholine, thiomorpholine, piperazine, piperidine or diazepine.

12. (canceled)

13. (previously presented): The compound of claim 1, wherein n is 2-3.

14. (previously presented): The compound of claim 1, wherein NR^3R^4 is an acyclic amine, or guanidinyll or a tautomer thereof.

15. (previously presented): The compound of claim 1, wherein R^3 and R^4 together with N form an optionally substituted morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

16. (previously presented): The compound of claim 1, wherein W is NR^1R^2 ; and Z is $\text{NR}^1 - (\text{CR}^1_2)_n - \text{NR}^3\text{R}^4$

wherein R^1 and R^2 are as defined in claim 1; and

R^3 and R^4 together with N in NR^3R^4 form an optionally substituted ring.

17. (previously presented): The compound of claim 16, wherein R^3 and R^4 together with N form an optionally substituted morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

18. (previously presented): The compound of claim 19, wherein said optionally substituted ring is optionally substituted with amino, carbamate, a C_{1-10} alkyl containing one or more non-adjacent N, O or S, and optionally substituted with a heterocyclic ring; aryl or a saturated or unsaturated heterocyclic ring.

19. (previously presented): The compound of claim 16, wherein R^1 and R^2 together with N in NR^1R^2 form an optionally substituted ring selected from the group consisting of tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-*b*]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, and 2,3,4,4a,9,9a-hexahydro-1H- β -carboline.

20. (previously presented): The compound of claim 19, wherein R^1 and R^2 together with N in NR^1R^2 form an optionally substituted morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

21. (previously presented): The compound of claim 17, wherein R^3 and R^4 together with N in NR^3R^4 form an optionally substituted pyrrolidine.











22. (previously presented): The compound of claim 21, wherein said pyrrolidine is substituted with pyrazine.


23. (canceled)

24. (currently amended): The compound of claim 1, wherein each optionally substituted moiety is substituted with one or more halo, OR^2 , NR^1R^2 , carbamate, C_{1-10} alkyl, C_{2-10} alkenyl, each optionally substituted by halo, =O, aryl or one or more heteroatoms; ~~inorganic substituents~~, aryl, carbocyclic or a heterocyclic ring.

25. (original): The compound of claim 1, wherein said compound is chiral.

26. (previously presented): The compound of claim 1, wherein said compound is selected from the group consisting of:





27. (original): A pharmaceutical composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier.

28. (withdrawn): A method for identifying a compound that interacts with a quadruplex-forming region of DNA, comprising

- a) contacting a nucleic acid capable of forming a quadruplex with a primer comprising a label to form a complex;
- b) contacting said complex with one or more test compounds and a polymerase to form a reaction mixture, and
- c) separating said reaction mixture by capillary electrophoresis to obtain one or more reaction products; and
- d) determining the extent of primer extension in said one or more reaction products.

29. (withdrawn) The method of claim 28, further comprising the step of determining the binding affinity of said one or more test compounds for said nucleic acid.

30. (withdrawn) The method of claim 28, wherein said label is a fluorescent label.

31. (previously presented): A method for treating a cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby treating said cell-proliferative disorder.

32. (original): The method of claim 31, wherein said cell proliferative disorder is cancer.

33. (original): The method of claim 31, wherein cell proliferation is reduced, or cell death is induced.

34. (original): The method of claim 31, wherein said subject is human or an animal.

35. (currently amended): A method for ~~reducing~~ treating a cell proliferative disorder ~~proliferation~~ or inducing cell death, comprising contacting a system with an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby treating a cell proliferative disorder or inducing cell death in said system.

36. (original): The method of claim 35, wherein said system is a cell or tissue.

37-42. (canceled)

43. (new) The method of claim 31, wherein said cell proliferative disorder is colon cancer.